Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
10.74
-0.08 (-0.74%)
Apr 13, 2026, 1:25 PM EDT - Market open
Arvinas Revenue
In the year 2025, Arvinas had annual revenue of $262.60M, down -0.30%. Arvinas had revenue of $9.50M in the quarter ending December 31, 2025, a decrease of -83.95%.
Revenue (ttm)
$262.60M
Revenue Growth
-0.30%
P/S Ratio
2.64
Revenue / Employee
$1,067,480
Employees
246
Market Cap
686.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.60M | -800.00K | -0.30% |
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.86K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionARVN News
- 26 days ago - Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days - GlobeNewsWire
- 4 weeks ago - Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders - GlobeNewsWire
- 6 weeks ago - Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewsWire
- 2 months ago - Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director - GlobeNewsWire
- 4 months ago - Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 4 months ago - Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire